Product Images Doxorubicin Hydrochloride

This text appears to be a list of medical trials, however, it is difficult to determine the specific details of each trial based on the provided text.*

This is a description of a medication called DOXOrubicin Hydrochloride for Injection, USP. It is a cytotoxic agent used for intravenous use only, and it is contained in 10 single-dose vials. Each vial contains 20 mg of Doxorubicin Hydrochloride, USP (equivalent to 18.74 mg of doxorubicin free base) and Lactose Monohydrate 100 mg. The medication is reconstituted with 10 mL 0.9% Sodium Chloride Injection, USP, and is stable for 7 days at room temperature and 15 days under refrigeration after reconstitution. It is a strong medication and should not be prescribed without thorough knowledge of dose, indications, and toxicity. Severe cellulitis, vesication, and tissue necrosis may occur if Doxorubicin is extravasated during administration. It is manufactured by Amneal Oncology Pvt. Ltd. in India and distributed by Amneal Pharmaceuticals LLC in Bridgewater, New Jersey.*

This document is a package insert for a medication called Doxorubicin, manufactured by Amneal Oncology Pvt. Ltd. The medication is a cytotoxic agent and should not be prescribed without knowledge of the dose, indications, and toxicity. The medication comes in a single-dose vial and is intended for intravenous use only. The package insert provides information on dosage, storage, and administration. It is advised to shake well to dissolve and retain the vial in the carton until the time of use. The document also includes a warning that severe cellulitis, vesication, and tissue necrosis will occur if the medication is extravasated during administration.*

This is a package insert for DOXOrubicin Hydrochloride, which is a cytotoxic agent administered via intravenous injection. The vial contains 50mg of Doxorubicin Hydrochloride and 250mg of Lactose Monohydrate. It needs to be reconstituted with 25 mL of 0.9% Sodium Chioride Injection, USP prior to administration. After reconstitution, the solution is stable for 7 days at room temperature and 15 days under refrigeration. It should be stored unreconstituted at 20° to 25°C. The drug is manufactured by Amneal Oncology Pvt. Ltd., Telangana 509301, INDIA and is distributed by Amneal Pharmaceuticals LLC, Bridgewater NJ 08807. The usual dosage and complete prescribing information can be obtained from the package insert. It is important to have a thorough knowledge of the dose, indications, and toxicity before prescribing this drug, as severe cellulitis, vesication, and tissue necrosis will occur if it is extravasated during administration.*

This is a description of a medication called DOXOrubicin Hydrochloride for Injection, USP. This drug is to be used intravenously and is packaged in a single-dose vial. Each vial contains 50mg of the drug equivalent to 46.86mg of doxorubicin free bese. The medication should be reconstituted with 25ml 0.9% Sodum Choride infction, USP and should be stored at 20°C to 25°C. The drugs should be protected from light, and any unused portion should be discarded. Administering DOXOrubicin incorrectly can lead to severe cellulitis, vesication, and tissue necrosis. The medication is manufactured by Amneal Oncology Pvt. Ltd. in Telangana.*